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Background: Erythropoietin (EPO), the hormone involved in red blood cell 
production, activates its receptor by binding to the receptor’s extracellular 
domain and presumably dimerizing two receptor monomers to initiate signal 
transduction. EPO-mimetic peptides, such as EMPI, also bind and activate the 
receptor by dimerization. These mimetic peptides are not as potent as EPO, 
however. The crystal structure of the EPO receptor (EBP) bound to EMPl 
reveals the formation of a complex consisting of two peptides bound to two 
receptors, so we sought to improve the biological activity of EPO-mimetic 
peptides by constructing covalent dimers of EMPI and other peptide mimetics 
linked by polyethylene glycol (PEG). 
Results: The potency of the PEG-dimerized EPO peptide mimetics both in 
vitro and in viva was improved up to 1 ,OOO-fold compared to the corresponding 
peptide monomers. The dimers were constructed using peptide monomers 
which have only one reactive amine per molecule, allowing us to conclude that 
the increase in potency can be attributed to a structure in which two peptides 
are linked through their respective amino termini to the difunctional PEG 
molecule. In addition, an inactive peptide was converted into a weak agonist by 
PEG-induced dimerization. 
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Conclusions: The potency of previously isolated peptides ttiat are modest 
agonists of the EPO receptor was dramatically increased by PEG-induced 
dimerization. The EPO receptor is thought to be dimerized during activation, so 
our results are consistent with the proposed 2:2 receptor : peptide 
stoichiometry. The conversion of an inactive peptide into an agonist further 
supports the idea that dimerization can mediate receptor activation. 
Introduction 
The regulation of red blood cell production is under the 
control of the glycoprotein hormone erythropoietin (EPO) 
[1,2]. EPO is made in the mammalian kidney in response 
to hypoxia (low circulating oxygen levels), and released 
into the circulation to stimulate the maturation and differ- 
entiation of erythroid red blood cell precursors. Certain 
pathological conditions result in low or inadequate pro- 
duction of EPO and recombinant human EPO has been 
developed as a therapeutic to treat the resultant 
anemia [Z]. The proliferative properties of EPO are medi- 
ated through its interaction with, and activation of, a 
type-1 cytokine receptor, a transmembrane protein, found 
on responsive cells, that is thought to be activated via a 
dimerization mechanism [3-S]. 
Recently, a family of EPO-receptor agonist peptides have 
been discovered [6] and the X-ray crystal structure of an 
EPO-mimetic peptide bound to the extracellular ligand 
binding domain (erythropoietin binding protein; EBP) of 
the EPO receptor was reported [7]. The X-ray structure 
revealed that two mimetic peptide monomers mediate the 
dimerization of the EPO receptor in a 22 peptide : recep- 
tor complex. Solution-phase experiments have demon- 
strated that an EBP dimer can be effectively stabilized for 
study using a chemical cross-linking reagent [7]. Other 
experiments have shown that the EPO receptor can be 
activated by antibodies that dimerize the receptor [8,9] or 
by mutations that allow two EPO receptors to become 
covalently dimerized by the formation of novel disulfide 
bonds [lo-121. Evidence suggests that EPO itself can 
promote dimerization of its EBP domain in solution [13]. 
Further, evidence shows that other type-1 cytokine recep- 
tors, such as the growth hormone receptor, exist as dimers 
with their cognate ligands, suggesting that receptor 
dimerization plays a critical role in activation of this recep- 
tor class [14]. The EPO receptor agonists identified by 
Wrighton et al. [6] activate the EPO receptor but display 
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1 The general route taken to generate the PEG- coupled peptide dimers used in these studies. 
potency significantly less than EPO. We postulated that contains two potentially reactive amines, one at the amino 
this was due to the thermodynamically unfavorable four- terminus of the peptide and one in the sidechain of the 
membered peptide-receptor complex that needs to form. single lysine within the peptide sequence, GGTYSCHFG- 
Here, we demonstrate that the biological activity of an PLTWVCKPQGG (single-letter amino acid code), so that a 
EPO mimetic peptide can be significantly improved by number of different connectivities between the two mol- 
covalent dimerization. The overall entropic disadvantage ecules are possible. A monofunctional PEGS,000 with a 
of a 22 receptor:ligand interaction is’reduced by converting single reactive succinimidyl group was used as a control; 
it into a 2:l receptor:ligand interaction. Furthermore, we this species could potentially couple to either or both of the 
show that an inactive mimetic peptide can be converted peptide amines. The total estimated mass of the PEG 
into a weak agonist by covalent peptide dimerization with dimer and a monoconjugated PEG peptide would be 
a polyethylene glycol (PEG) linker. similar using these strategies. 
Results and discussion 
The mechanism for EPO receptor activation appears to be 
related to receptor dimerization, and the EPO mimetic pep- 
tides appear to act in this way also [7]. To probe this bio- 
chemical mechanism further, we sought to utilize simple 
dimers of synthetic peptides as probes of the receptor acti- 
vation mechanism. Our approach employed an amine-reac- 
tive difunctional PEG molecule, succinimidyl propionate 
(SPA&-PEG, to form a linear polymer molecule with EPO 
mimetic peptides on each end. The difunctional activated 
PEG used in these experiments has an approximate mol- 
ecular weight (MW) of 3,400 and has amine-reactive succin- 
imidyl groups at both ends. This reactivity was used to 
couple two equivalents of EMPl (MW = 2,092; an EPO 
receptor agonist peptide) to the polymer with the concomi- 
tant liberation of two succinimidyl moieties resulting in a 
PEG-(EMPl), product (MW = -7,600; Figure 1). EMPl 
The difunctional reaction was carried out with EMPl in 
excess, and the major reaction product was monitored 
(Figure 2) and purified by reverse-phase high performance 
liquid chromatography (HPLC). Under these analytical 
conditions the (SPA), polymer and Tris-inactivated 
polymer did not appear to bind the column, whereas a 
major reaction product with a retention time of 37 min was 
identified (Figure 2~). EMPl demonstrated a retention 
time of 35 min, and the excess peptide utilized in the reac- 
tion was clearly distinguishable from the nascent reaction 
product. Analysis of the recovered material after prepara- 
tive chromatography using analytical reverse-phase HPLC 
showed a single species with a retention time similar to the 
major reaction product before purification (Figure 2d for 
EMPl-PEG dimer; representative data shown for EMPl 
only). The recovered product was lyophilized to dryness, 
resuspended and examined for the ability to compete with 
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Reverse-phase HPLC analysis of (SPA),-PEG reaction with EMPl . 
Experimental conditions are described in the text. (a) (SPA), polymer 
does not bind to the column under the analytical conditions employed. 
(b) EMPl demonstrated a retention time of -35 min. (c) The crude 
reaction mix after Tris-HCI quench shows a main product peak at 
37 min and unreacted EMPl at 35 min. (d) Reinjection of the main 
product peak after preparative HPLC purification and lyophilization 
demonstrates a single species at -37 min. 
[1251]-labeled EPO for receptor binding, laser desorption 
mass spectral analysis, and for the ability to support the 
proliferation of EPO-responsive cells. Similar experimental 
protocols were used for all PEG-dimer peptides and 
PEG-monomer peptides reported in this study. 
Matrix-assisted laser desorption/ionization-time of flight 
(MALDI-TOF) mass spectral analysis supports the pres- 
ence of the expected dimeric product of EMPl 
(Figure 3a), as indicated by a predominant species with a 
centroid mass of 7,835 (expected charge to mass ratio 
[m/z] of about 7,600; see Table 1). Use of this analytical 
tool may, however, have resulted in the fragmentation of 
the molecule, because a molecular species corresponding 
to a peptide-PEG monomer (5,775 m/z) was also 
observed. The complexity of this spectra was unex- 
pected, and further investigation of the main reaction 
product by electrospray mass spectrometry resulted in 
the observation that the purified product could not be 
ionized using this technique, suggesting that a single 
non-ionizable species was present in the sample. An alter- 
native explanation is that some amount of PEG-peptide 
product is present along with the dimer. In either case, 
the dimer peptide product was easily identifiable. Other 
peptides in the series demonstrate much simpler spectra: 
a single species more stable to ionization is indicated in 
the EMP16-PEG dimer spectrum (Figure 3b; expected 
m/z of about 7,550, observed 7,559) and in the 
EMP24-PEG dimer spectrum (Figure 3c; expected m/z 
of about 6,300, observed 6,327). The dimer reaction prod- 
ucts were recovered from conjugation mixtures where the 
peptide was in excess so as to limit monoconjugation and 
enhance dimer formation. Monoconjugation and diconju- 
gation of EMPl were clearly demonstrated through the 
use of a monovalent PEG 5,000 (see Figure 3d) to afford a 
control sample of matched molecular weight (expected 
m/z of about 7,100,. observed 7,096) and a diconjugated 
peptide as well (Table 1). Historically the analysis of 
PEG-containing biopolymers has proven problematic [15] 
and there appears to be an observed difference in the 
behavior of the PEG-peptide conjugate molecules even 
though a similar chemical linkage is employed in the 
dimerization of these peptides. Mass spectral and yield 
data for all peptides are summarized in Table 1. 
Competitive binding analysis of EMPl dimers on EBP 
beads revealed a 50% inhibitory concentration (IC,,) of 
20pM for the purified dimer, a value four-fold greater 
than that for EMPl monomers in the same assay (Table 2 
and Figure 4) indicating some loss of binding avidity upon 
PEG conjugation. Polymer alone, when inactivated by 
treatment with Tris-HCl, demonstrated a detectable com- 
petition binding signal but this signal was modest (~10%) 
at the IC,, of the PEG-EMPl dimer. In general, when 
analyzed by this method, all dimer peptides suffered a 
modest loss in competitive binding ability, as shown in 
Table 2. This is not the case for intact EPO receptors on 
cells, however: the respective EMPl peptide dimers 
demonstrate slightly improved binding as compared to the 
monomer peptide (0.02 pM and 0.07 pM, respectively). 
The difference in these values is likely to be due to differ- 
ences in assay formats: the immobilized EBP system 
would not be expected to allow receptor dimerization, 
whereas the cell-associated receptors should dimerize 
freely upon peptide binding. 
EPO-responsive cell proliferation studies were performed 
on cells expressing the murine, truncated human or native 
human EPO receptors, and the PEG-EMPl dimer 
demonstrated 50% effective dose (ED,,; the amount of 
peptide required to stimulate [3H]thymidine incorporation 
by 50% of the experimental maximum) values of 0.01, 
0.0015 and 0.001 pM, respectively (Table 2 and Figure 5). 
In all three cell lines, the parent peptide, EMPl, demon- 
strated an ED,, of 0.1 pM, indicating a lo-fold increase in 
potency in the murine receptor line and almost 60- or lOO- 
fold in the cells expressing human receptors. These EDS, 
data clearly demonstrate that the covalent dimers are sig- 
nificantly more active than the parent monomers. Polymer 
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MALDI-TOF mass spectral analysis. Conditions were as described in of the EMPl -PEG monoconjugate. All main centroid masses are 
the text. (a) Spectrum of EMPl dimer. (b) Spectrum of the EMP16 consistent with the expected dimeric or monomeric peptide-PEG 
dimer product. (c) Spectrum of EMP24 dimer product. (d) Spectrum species. 
alone, when inactivated by treatment with Tris-HCl, A second EPO mimetic peptide, EMP16, with the 
demonstrated no activity in the cell proliferation assay. sequence GGTYSCHFGPLTWVCKPQ [ 161, was sub- 
These values are determined with the concentration jected to a similar PEG-dimerization protocol to that 
reported in terms of micromoles of molecules so that each described above for EMPl. This peptide is more active 
micromole of peptide dimer contains two equivalents of than EMPl in the cell proliferation assay in vitro as well 
peptide monomer. Given that these values are at least as in the exhypoxic mouse bioassay in vko. The dimer 
lo-fold greater than the monomer peptide values, a simple product of PEG-EMP16 was more active on the murine 
increase in effective peptide concentration cannot account and truncated human cell lines than the unconjugated 
for the difference in activity. parent compound, but the gain in potency was much 
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Table 1 
Yield of peptide conjugation reaction and apparent molecular mass of product. 
Peptide Sequence Mass Conjugation reagent Main product mass 
(centroid m/z) 
Yield 
(o/o of theoretical) 
EMPl GGTYSCHFGPLTWVCKPQGG 2092 (SPA&-PEG (MW -3400) 7835 69 
m-SPA-PEG (MW -5000) 7096 (peak 1) 
12036 (peak 2) 
EMP16 GGTYSCHFGPLTWVCKPQ 1978 (SPA),-PEG 7559 54 
EMP34 AC-GGTYSCHFGPLTWVCKPQGG 2133 (SPA),-PEG 7862 30 
EMP35 GGLYACHMGPMTWVCGPLRG 2177 (SPA),-PEG 7872 37 
EMP24 SCHFGPLTWVCK 1375 (SPA),-PEG 8327 45 
See Figure 3 for further details. 
more modest (Table 2). Unexpectedly, the EMP16-PEG 
dimer demonstrated reduced activity for the cell line 
bearing the native human receptor, about 1.7-fold less 
than the parent peptide. The reason for this is unclear 
but appears to reside in the differing ability of the 
peptide-dimer to mediate receptor activation in the 
cytoplasmic space upon peptide dimerization, given that 
essentially no change in the ability to compete for 
[‘*sI]-labeled EPO binding was observed (Table 2). This 
is not unreasonable considering the difference in the 
control regions of these two receptors: the truncated 
receptor has been manipulated to delete the 40 carboxy- 
terminal amino acid residues, which have been sug- 
gested to contain negative regulatory control elements. 
In any case, the experimental evidence derived from the 
murine and truncated human cell lines suggests that 
dimerization of the peptides with PEG can result in 
improved potency but that it does not work uniformly on 
all peptide sequences. 
Determination of the exact connectivity of the two pep- 
tides with PEG within the EMPl-PEG dimer and the 
EMP16-PEG dimer was problematic, because each 
peptide molecule had two potentially reactive amines (a 
free a-amino terminus and an E-amine on a lysine 
sidechain). To explore further the effect of connectivity in 
these molecules, we PEG-dimerized peptide molecules 
that contain only an internal lysine group by using an 
EMPl analog acetylated at the amino terminus (EMP34) 
and a sequence analog (EMP35) which has only one reac- 
tive amino-terminal amine. In vitro proliferation studies 
with these compounds suggest that potential dimerization 
through the free amino terminus has the most profound 
effect on bioactivity giving rise to a species up to lOOO-fold 
more active than the monomeric parent peptide 
(EMP35-PEG dimer; Table 2). Conjugation through the 
lysine sidechain had a limited or a negative effect on activ- 
ity (EMP34-PEG dimer) as did mono- or di-PEG conjuga- 
tion (Table 3). These data support the conclusion that the 
Table 2 
EPO receptor binding and cell proliferation studies. 
EPO competitive binding IC,, (FM) 
Peptide EBP beads EPO receptor 
EMPl 5 0.07 
EMPl -PEG dimer 20 0.02 
EMPl6 8 0.07 
EMPl6-PEG dimer 15 0.02 
EMP34 (N-acetyl) 20 ND 
EMP34-PEG dimer 60 ND 
EMP35 (terminal NH,) 3 0.2 
EMPBB-PEG dimer 15 0.0025 
Tris inactivated polymer 300 ND 
Murine receptor 
0.1 
0.01 (10X) 
0.08 
0.01 (8X) 
0.03 
0.2 (-7X) 
0.1 
0.006 (16X) 
IA 
EPO ED,, (PM) 
Truncated 
human receptor 
0.1 
0.0015 (67X) 
0.02 
0.002 (1 OX) 
0.06 
0.05 
0.08 
0.001 (80X) 
IA 
Human receptor 
0.1 
0.001 (100X) 
0.0115 
0.02 (-1.7X) 
0.01 
0.2 (-20X) 
0.1 
0.0001 (1000X) 
IA 
ND, not determined. IA, inactive. See Figure 4 and text for further details. 
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Figure 4 
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Graphic representation of the analysis of the competitive binding of the EMPl dimer and EMPl with [ ts51]-labeled EPO to (a) EBP beads or(b) 
TF-1 cells. These data are summarized numerically in Table 2; see text for further details. 
creation of a head-to-head dimer (both peptides attached enhances the potency of EPO-mimetic peptides, and 
through the amino terminus) using a PEG linker greatly approaches a level almost lOOO-fold greater than the free 
Figure 5 
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Cell proliferation studies with EMPl and the EMPl dimer on cells bearing truncated (a) human or(b) murine EPO receptors. The increase in activity at 
the same concentration of dimeric or monomeric peptides is striking. These data are numerically summarized in Table 2; further details are in the text, 
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Table 3 
Analysis of nondimer PEG conjugates of EMPl. 
Peptide EPO Competitive Binding IC,, (PM) EPO-ED,, (PM) 
m-SPA-PEGIEMPl 7096 mass 60 
m-SPA-PEGIEMPl, 12036 mass 40 
Murine receptor 
2.0 
1 
Truncated human receptor 
0.4 
0.1 
Human receptor 
0.5 
0.6 
parent peptide (EMP35 versus EMP35 dimer; Table 2). 
Furthermore, this effect was not observed upon simple 
covalent attachment of linear PEG to EMPl (Table 3), 
indicating that dimerization is the critical determinant for 
this increased activity. The more active component in the 
EMPl-PEG dimer is likely to be the amino-terminal 
dimer, because conjugation of the amino-terminal acety- 
lated EMP34 occurs at a greatly reduced rate and requires 
a much longer conjugation time than does EMPl (see 
Materials and methods section). The amino- and carboxy- 
terminal glycine residues of EMPl were not visualized in 
the X-ray crystal structure, so the exact role played by the 
terminal residues is unclear [7,16]. It should be noted that 
the individual peptide sequence and the placement of the 
terminal glycines appear to be essential determinants of 
the level of increased activity or whether any increase is 
observed at all [ 161. 
Obvious from the data presented above is the conclusion 
that the attachment of the PEG polymer to the amino ter- 
minus of the two peptide monomers does not result in any 
Figure 6 
steric hinderance which would prevent the interaction of 
the peptide dimer with the two receptors. Examination of 
the crystal structure [7] suggests that the peptide termini 
point out into space above the two receptor subunits, so 
that attachment of the polymer would not be expected to 
compromise the ability of the peptide to interact with the 
receptor monomers. Indeed, covalent EMPl dimers linked 
via the carboxyl terminus of EMPl also appear to have 
improved receptor activation potential [17]. To confirm 
that the peptide dimers retained the ability to dimerize 
EBP in solution, however, a bifunctional sulphydryl reac- 
tive cross-linker (DPDPB) was used to capture and stabi- 
lize a mimetic-dependent EBP dimeric structure [7]. As 
shown in Figure 6, a dimeric EBP product is formed upon 
co-incubation of the peptide, EMPl (or EMPl dimer), 
DPDPB and EBP. The receptor dimer product is identical 
in the two different peptide preparations because a cova- 
lent bond joins two EBP monomers and the peptides are 
apparently released during electrophoretic separation in 
the presence of sodium dodecyl sulfate (SDS). These data 
support the idea that EMPl and the EMPl dimer mediate 
SDS-PAGE analysis of DPDPB cross-linking 
of EBP in the presence of EMPl or the EMPl 
dimer. Peptides and EBP (22pM) were 
incubated in the presence of the 
heterobifunctional sulfhydryl-reactive cross- 
linking reagent DPDPB (1 .l mM) in matched 
reagent mixtures which differ only by the 
concentration of (a) EMPl or(b) the EMPl 
dimer. Lane 1 contains molecular weight 
markers of 14.4, 20.1,30, 43, 63 and 94 kDa; 
lane 2: EBP (5 pg); lane 3: EBP, DPDPB, 
EMPl (40 FM); lane 4: EBP, DPDPB, EMPl 
(20 PM); lane 5: EBP, DPDPB, EMPl 
(10 FM); lane 6: EBP, DPDPB, EMPl (5 PM); 
lane 7: EBP, DPDPB, EMPl (1 FM); lane 8: 
EBP, DPDPB, EMPl (0.5 PM); lane 9: EBP, 
DPDPB, EMPl (0.25 PM); lane 10: EBP, no 
DPDPB, EMPl (40 PM); lane 11: EBP, 
DPDPB, no EMPl ; Lane 12: no EBP, 
DPDPB, EMPl (40 uM). (b) The same lanes 
but with the EMPl dimer in place of EMPl. 
Both EMPl and the EMPl dimer promote the 
concentration-dependent formation of 
receptor dimer which is captured by DPDPB. 
The EMPl dimer appears to produce slightly a small amount of receptor dimer that can be 
more dimer product at each concentration. In reversed with reducing agents (data not 
the absence of cross-linker (lane 10) both shown) presumably acting through the lone 
EMPl and the dimer promote the formation of free sulphydryl on EBP. 
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(a) 
v) 
5 0 20 
I  -  
Epo units per mouse EMP35 (nmol) per mouse 
W 
” I>” 51 I 
Epo units per mouse EMP35 dimer (nmol) per mouse 
Chemistry & Blolog) 
Exhypoxic mouse bioassay. (a) Stimulation of 
[5gFe] incorporation into nascent red blood 
cells by EPO and EMP35. (b) Stimulation of 
[5gFeI incorporation into nascent red blood 
cells by EPO and the EMP35 dimer. 
formation of a soluble receptor dimer, and from this it can 
be concluded that EBP dimerization is a property of the 
EPO mimetics, EMPl and the EMPl dimer. 
To investigate the ability of EMP-PEG dimers to retain 
bioactivity in ak, and to examine any potential increase in 
bioactivity, they were studied in the exhypoxic poly- 
cythemic mouse bioassay (see Materials and methods 
section; Figure 7 and Table 4). This assay is frequently 
used to estimate the ability of an exogenously adminis- 
tered compound to induce new red blood cell synthesis or 
to function as EPO or an EPO mimetic. The numbers 
reported here were generated from sets of 10 animals for 
each experimental dose, and the data suggest that, on a 
mole-equivalent basis, the EMPl-PEG dimer is about 
lo-fold more active than EMP. This value is consistent 
with the differential effect of the dimer peptide on the 
murine as compared to truncated or full length human 
EPO receptor cell lines in vitro, in which increased potency 
values were seen, of lo- and 60-lOO-fold, respectively. 
Clearly, the dimers do not activate the murine receptors as 
efficiently as they do the human receptors and this is con- 
firmed with the results in viva. The EMP16 dimer does not 
demonstrate significantly increased potency over the 
monomer peptide in vitro, and examination in vivo con- 
firmed that the dimer does not have increased potency. In 
contrast, the EMP35 dimer demonstrated an in &vo 
improvement of 257-fold over the monomer parent (equiv- 
alency values of 18 and 0.07 for the monomer and dimer 
respectively; Table 4). 
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Table 4 Figure 8 
Approximate equivalency of EPO and mimetic peptides in vivo. I 
Peptide Amount of peptide equivalent to 
0.025 units of EPO (nmoi) 
h -D- EMP24 
0 45,000 
; & EMP24 dimer 
EMPl 3.8 
EMPl dimer 0.28 
EMPl6 0.5 
EMP16 dimer 0.45 
EMP35 18 
EMP35 dimer 0.07 
EPO 0.0000058 
40,000 - 
T 
35,000 - 
I , I., ’ I I I I 
0.0001 0.001 0.01 0.1 0.5 1 5 IO 
Given that the 257-fold improvement in equivalence for 
the EMP35 dimer was significantly greater than the 16- 
fold increase seen in the murine receptor proliferation 
studies, it is reasonable to suggest that some other factor is 
responsible for this level of potency. Given that PEG con- 
jugation of polypeptides often translates into increased 
serum half-life and reduced immunogenicity [IS], PEG 
modification of the EMP35 dimer may have significantly 
increased its potency in vjvo as a result of this combination 
of effects along with improved proliferative properties. 
From these data it can be reasonably speculated that the 
full increase in potency on human EPO receptor-bearing 
cells might be exhibited in vjvo in nonhuman primates or 
in humans; confirmation of this conjecture awaits study in 
these species. Even with the improved potency of the 
PEG dimers, however, it remains clear that much effort 
will be required to achieve the level of potency of the EPO 
molecule itself, which is many times that of the EMP35 
dimer. This may be due to the symmetrical fashion in 
which the two peptides interact with the EPO receptor, 
whereas the interaction of EPO itself with the receptor 
would be expected to be asymmetric [7]; this could lead to 
differences in the receptor signaling assembly which would 
preclude full activation with the symmetrical mimetic 
peptide even when it is dimerized. 
Effect of PEG dimerization on EMP24 activity in EPO-responsive ceil- 
proliferation studies in FDC-Pl -derived cell lines containing a human 
EPO receptor. The peptide alone does not induce proliferation of the 
EPO-responsive ceils, but after PEG dimerization a weak but 
significant agonist effect is seen. Approximately twice as many counts 
per minute (cpm) were incorporated by cells incubated with 1 O+ M 
peptide dimer compared to ceils incubated with 1 OY5 M peptide 
monomer. The replicate error bars represent the standard deviation of 
four assay points per concentration of peptide or peptide dimer. 
shown). It has previously been speculated that such an 
antagonist to agonist conversion may be possible for ligands 
that bind, but do not activate, receptors that use dimeriza- 
tion activation mechanisms [18,19]. Although we have pro- 
vided minimal evidence for such a conversion with 
EMP24, several other inactive EMPl derivatives [16], 
including EMP6 (Tyr4 + Ala) and EMP7 (Tyr4 + Thr), 
were not converted to agonists using this method (data not 
shown). It is possible in these cases that PEG-dimerization 
resulted in a structure that did not allow productive recep- 
tor dimerization. This observation makes general applica- 
tion of this technique problematic and suggests that other 
unknown criteria must be satisfied in order to change an 
inactive peptide into an agonist. 
Significance 
Furthermore, we have shown that EMP ‘24, an inactive 
truncation analog of EMPl (SCHFGPLTWVCK; which 
lacks the tyrosine critical for receptor dimerization) [ 161 can 
be converted to a weak agonist for the human EPO recep- 
tor cell line by PEG dimerization (Figure 8). A 10m5 M con- 
centration of the parent peptide has no activity above 
background whereas the dimeric peptide at the same con- 
centration results in a level of proliferation that incorporates 
twice as many counts per minute (cpm) of [3H]thymidine 
over background levels of DNA synthesis. This inactive to 
active conversion appears to be limited to the human EPO 
receptor cell line, because the EMP24 dimer did not act as 
an agonist on the murine EPO receptor cell line (data not 
The glycoprotein hormone erythropoietin (EPO) is 
responsible for regulating red blood cell production. Low 
EPO levels or inadequate production of EPO exists in a 
number of pathological conditions, and recombinant EPO 
can be used to treat the resulting anemia. EPO binds to 
the extracellular portion of its receptor and activation is 
thought to occur by ligand-dependent dimerization of two 
receptors which initiates EPO signal transduction. A 
family of EPO receptor agonist peptides was recently dis- 
covered and may provide the basis for future therapeutic 
agents. The agonist peptides bind to the EPO receptor but 
do not activate the receptor as effectively as EPO does. 
We have improved the potency of these mimetic peptides 
by dimerizing them with a polyethylene glycol (PEG) 
Concentration (KM) Chemistry 6 Biology 
948 Chemistry & Biology 1997, Vol4 No 12 
linker. The PEG-peptide dimers activate the receptor up 
receptors whose active form is ultimately composed of 
to lOOO-fold more efficiently in vitro (EMP35) and are 
more effective in an assay in vivo. Upon PEG-dimeriza- 
two or more heterologous proteins (receptor heterodimers 
tion the additional molecular bulk of the agents with 
improved potency retain the ability to dimerize the extra- 
or receptor oligomers). Receptor and protein dimerization 
cellular domain of the EPO receptor (EPO binding 
protein, EBP). Not all peptides, such as EMP16, 
activation mechanisms have emerged as an important 
however, respond in the same manner and individual 
experimentation is required to investigate the possibility 
fundamental concept, and the design of small molecules 
for improved potency. The observation that at least one 
inactive peptide can be converted into a weak agonist 
demonstrates the potential of the method described here 
and suggests that the possibility of activating receptors by 
dimerization of compounds with simple binding capacity 
exists, provided that they do not induce an inactive recep- 
tor conformation. This methodology might be extended to 
other peptidic and nonpeptidic pharmacophores (the part 
of a molecule causing the specific physiological effects or 
binding interactions) which bind to other receptors. The 
potency of peptide ligands for other receptors thought to 
have simple dimerization activation mechanisms, such as 
the thrombopoietin receptor, have been shown to benefit 
from dimerization [20]. The optimal size of the PEG mol- 
ecules used in this study has not yet been fully explored 
and it is reasonable to expect that activation of different 
receptors will require the use of different PEGS. It is also 
possible that a difunctional PEG with two different chem- 
ical reactivities could be used to form heterodimers of two 
different peptides or compounds in order to activate 
Mono-PEG conjugation of EMPf. Mono-PEG conjugates of EMPl 
peptide were made using the monofunctional amine reactive polymer 
analog m-SPA-PEG. The conjugation reaction was carried out with 
polymer in excess (-three-fold) by suspending 142.5 mg 
(0.0286 mmol, MW -5,000) of polymer in 4ml PBS, pH 7.5, and 
adding 20mg EMPl (0.0095 mmol, MW 2,092) dissolved in 1 ml of 
0.1% trifluoroacetic acid (TFA) and the mixture was incubated on ice 
for 20 h. At that time, the reaction was adjusted to a final concentration 
of 50mM Tris by addition of 1 M Tris-HCI, pH 7.5 and incubated on 
ice for 1 h. Analytical HPLC suggested that there were two main reac- 
tion products of essentially equivalent magnitude which were not base- 
line resolved. Preparative HPLC (using the flatter gradient system 
described below) and conservative cuts resulted in collection of two 
product peaks that eluted at -44 and -47 min. After lyophilization, 
24.8 mg and 16.5 mg of the two species were recovered, respectively. 
Mass spectral analysis of these two species demonstrated centroid 
masses of 7,096 (peak 1) and 12,036 (peak 2), indicating the coupling 
of one or two PEG molecules, respectively, to the peptide. 
PEG dimerization of EMP7. The dimerization of EMPl was carried out 
by suspending 25mg (0.0071 mmol) of (SPA), polymer [21] in 4ml 
PBS, pH 7.5, and adding a three-fold molar excess of EMPl 
(0.0213 mmol, 44.5 mg, MW 2092) dissolved in 1 ml of 0.1% TFA. 
The mixture was incubated on ice for 3 h, then an additional 7.5mg 
(0.0036 mmol) of lyophilized EMPl was added. The final ratio was 
3.5 moles of EMPl to 1 mole of (SPA&-PEG and the mixture was incu- 
bated for an additional 17 h on ice. At that time, the reaction was 
adjusted to a final concentration of 50 mM Tris by addition of 1 M 
Tris-HCI, pH 7.5 and incubated on ice for 1 h. After preparative HPLC 
and lyophilization 38mg of PEG dimer was recovered, which corre- 
sponds to a 69% yield: the theoretical yield was 55 mg, based on a 
calculated mass of 7,600 mg/mmol. 
EMPi (0.01’0 mmol, 2Omg, MW 1,978) dissolved in 0.25 ml of 0.1% 
PEG dimerizafion of EMPIG: The modification of EMP16 was carried 
TFA. This mixture was incubated on ice for 20 h. At that time, 0.25 ml of 
out by suspending 11.2 mg (0.0033 mmol) of (SPA), polymer in 2.5 ml 
PBS. DH 7.5. and addina an aooroximatelv three-fold molar excess of 
1 M Tris-HCI, pH 7.5 was added and the reaction mix was incubated at 
4°C for 1 h. The sample was subjected to analytical and preparative 
HPLC as below, with the main preparative reaction product peak 
eluting at -43 min. After preparative HPLC and lyophilization 13.3 mg 
which can effectivelv mimic these functions is an area of of PEG dimer was recovered, which corresponds to a 54% yield: the , 
intensive investigation. theoretical yield for this experiment was 24142 mg, based on- a calcu- 
lated mass of 7,400 mglmmol. 
Materials and methods 
Reagents 
SDS-PAGE gels (lo-20% gradient SDS-PAGE plates, 84 x 70 x 
1 .O mm, Integrated Separation Systems, Natick, MA) were stained with 
Coomassie Brilliant Blue R-250 (BioRad). A commercial preparation of 
activated difunctional polyethylene glycol (PEG-succinimidyl-propionate, 
(SPA),-PEG, mean MW -3,400) was purchased from Shearwater Poly 
mers, (Huntsville, AL) as was the monofunctional reagent, methoxy-PEG- 
succinimidyl-proprionate (m-SPA-PEG), MW -5,000. EMPl and all 
other peptides were obtained from the Peptide Synthesis Facility 
RWJ-PRI, (La Jolla, CA) and have been previously described 1161. These 
peptides were cyclized via oxidation of their intramolecular cysteines, ami- 
dated at the carboxyl terminus and mass confirmed by FAB-MS. All were 
Ellman-reaction negative. Tris base was obtained from BioRad, (Hercules, 
CA), and (1,4-Di-f3’-(2’-pyridyIdithio)propionamido]butane (DPDPB) and 
trifluoroacetic acid (HPLC grade) were obtained from Pierce Chemical 
Co (Rockford, IL). 
PEG peptide dimer and polymer preparations 
Tris inactivated polymer. Tris-inactivated polymer was formed by incuba- 
tion of 5 mM (SPA), polymer dissolved in phosphate buffered saline 
(PBS; Gibco, Gaithersburg, MD) with 50mM Tris-HCI, pH 7.5 added, 
and was used without further purification. 
PEG dimerizafion of fMP34: The dimerization of EMP34 was carried 
out by suspending 10.5 mg (0.0031 mmol) of (SPA), polymer in 2.5 ml 
PBS, pH 7.5, and adding an approximately three-fold molar excess of 
EMP34 (0.0094 mmol, 20 mg, MW 2,133) dissolved in 0.25 ml of 0.10/o 
TFA. This mixture was incubated at 4°C for 28 h. At that time, the reac- 
tion as monitored by HPLC was estimated to be approximately 30% 
complete, and the temperature was shifted to ambient. An additional 
27 h incubation provided no net increase in product. Because of possi- 
ble hydrolysis of the reactive polymer an additional 5 mg of polymer was 
added, and the incubation continued for an additional 16 h. At that time, 
0.25 ml of 1 M Tris-HCI, pH 7.5 was added and the reaction mix was 
incubated at 4°C for 1 h. The long reaction time of this conjugation was 
probably due to the structure of the peptide which was acetlyated at the 
amino terminus, leaving the internal lysine as the sole reactive amine. 
The sample was subjected to analytical and preparative HPLC (using 
the flatter gradient system described below) with the main preparative 
reaction product peak eluting at -48 min. After preparative HPLC and 
lyophilization, 10.4 mg of PEG dimer was recovered, corresponding to a 
30% yield: the theoretical yield for this experiment was 34.4 mg based 
on a calculated mass of 7,650 mg/mmol. 
PEG dimerization of EMP35: The modification of EMP35 was carried 
out by suspending 2.6 mg (0.00076 mmol) of (SPA), polymer in 
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3.0 ml PBS, pH 7.5, and adding a -37fold molar excess of EMP35 
(0.00229 mmol, 5 mg, MW 2,177) dissolved in 0.1 ml of 0.1% TFA. 
This mixture was incubated on ice for 26 h. At that time, 0.25 ml of 
1 M Tris-HCI, pH 7.5 was added and the reaction mix was incubated 
at 4% for 1 h. The sample was subjected to analytical and preparative 
HPLC (using the flatter gradient system described below) with the 
main preparative reaction product peak eluting at -46min. After 
preparative HPLC and lyophilization 2.2 mg of PEG dimer was recov- 
ered, corresponding to a 37% yield: the theoretical yield for this exper- 
iment was 24.42 mg based on a calculated mass of 7,400 mg/mmol. 
PEG dimerizafion of fMP24: The modification of EMP24 was carried 
out by suspending 1.2 mg (0.00036 mmol) of (SPA), polymer in 0.5 ml 
PBS, pH 7.5, and an approximately three-fold molar excess of EMP24 
(0.0011 mmol, 1.5 mg, MW 2,177) dissolved in 0.05 ml 0.1% TFA was 
added and the mixture was incubated on ice for 20 h. At that time, 
0.1 ml of 1 M Tris-HCI, pH 7.5 was added and the reaction mix was 
incubated at 4% for 1 h. The sample was subjected to purification 
using the analytical HPLC system described below with the main reac- 
tion product peak eluting at -38 min. After preparative HPLC and 
lyophilization 1 mg of PEG dimer was recovered, corresponding to a 
45% yield: the theoretical yield for this experiment was 2.2 mg based 
on a calculated mass of 6,150 mg/mmol. 
Analytical and preparative HPLC 
Over the course of the above reactions, the accumulation of product 
was monitored using analytical reverse-phase HPLC. The analysis was 
carried out using a Vydac C-l 8 Protein-Peptide column (0.46 x 25 cm, 
part no. 218TP54) and a Rainin Gradient HPLC system fitted with a 
Dynamax dual wavelength detector. At injection, the column was equili- 
brated in 0.1% TFA in dH,O and was developed with a 45 min linear 
gradient (O-100%) of acetonitrile (ACN) containing O.lo/, TFA begin- 
ning 10 min after injection. The flow rate was held constant at 1 mllmin. 
The main reaction product was purified by preparative reverse phase 
HPLC on the same chromatographic system using a Vydac C-18 
Protein-Peptide column (2.2 x 25 cm, no. 218TP15022). The reaction 
mix (6 ml) was injected after the column was equilibrated at 80:20, 
H,O:ACN (both containing 0.1% TFA), at a constant flow rate of 
8 mllmin. After a 20 min wash, bound species were eluted by applying 
a linear gradient of 100% ACNIO.l% TFA over 60 min. The major 
product peak eluting at 48 min, was collected and lyophilized to obtain 
EMPl -PEG dimer. These elution conditions were subsequently modi- 
fied to improve the resolution of some of the conjugation products 
(mPEG-EMPl, EMP34 and EMP35) from reaction by-products. This 
was accomplished by applying a flatter linear gradient of 20-800/o ace- 
tonitrile over 60 min. The variation in retention time due to different pep- 
tides and elution conditions is described as part of each synthesis, 
above. The materials recovered after lyophilization of the main product 
peak from each reaction were analyzed by analytical reverse-phase 
HPLC, MALDI-TOF mass spectrometry, EPO competitive binding 
potential and for bioactivity in vitro. 
Mass spectrometry 
The approximate molecular mass of the PEG-peptide dimers was 
determined by MALDI-TOF mass spectrometry on a Finnigan MAT 
mass analyzer equipped with a 337 nm pulsed nitrogen laser and oper- 
ated in the positive ion mode with 20 kV acceleration potential. The 
samples were prepared in an a-cyano-4-hydroxycinnamic acid matrix 
and the instrument was calibrated with an unrelated peptide or with 
bovine insulin. Alternatively, 4nitroaniline was used as the matrix and 
TFA omitted from the solvent for ionization under non-acidic conditions. 
EBP-based competition binding assay 
The extracellular domain of the human EPO receptor, EBP, was pro- 
duced and characterized as described [22]. EBP produced by this 
method contains one free sulfhydryl group at amino-acid position 181. 
In order to immobilize EBP to serve as the basis for a competition 
binding assay, this site was used for covalently attaching EBP to 
agarose beads [23,24]. Briefly, individual peptides were dissolved in 
dimethyl sulfoxide (DMSO) to prepare a stock solution of 1 mM. All 
reaction tubes contained 50 pl of EBP beads, 0.5 nM [1251]-labeled 
EPO and O-500 pM peptide in a total volume of 500 pL binding buffer 
(0.2% BSA in PBS). The final concentration of DMSO was adjusted to 
2.5% in all peptide assay tubes. Examination of the sensitivity of the 
assay to DMSO demonstrated that concentrations of up to 25% 
DMSO (v/v) had no deleterious effect on binding. Nonspecific binding 
was measured in each assay by inclusion of tubes containing a large 
excess of unlabelled EPO (1000 nM). Initial assay points with no added 
peptide were included in each assay to determine total binding. 
Binding mixtures were incubated overnight at room temperature with 
gentle rocking. The beads were then collected using Micro-columns 
(Isolab, Inc.) and washed with 3 ml of wash buffer (5% BSA in PBS). 
The columns containing the washed beads were placed in 12 x 75 mm 
glass tubes and bound radioactivity levels were determined in a gamma 
counter. The amount of bound [125i]-labeled EPO was expressed as a 
percentage of the control binding (total = 100%) and plotted against 
the peptide concentration after correction for nonspecific binding. The 
IC,, was defined as the concentration of the analyte which reduced the 
binding of [1251]-labeled EPO to the EBP beads by 50%. 
EPO receptor competition binding analysis 
TF-1 cells 1251 were maintained in RPMI 1640, loo/, fetal calf serum, 
lo/o L-glutamine, 1% penicillin, 0.1% streptomycin and 1 nglml of granu- 
locyte-macrophage colony stimulating factor (GM-CSF). [1251]-labeled 
EPO was obtained from NEN Research Products. Cells were cen- 
trifuged and washed once with binding buffer (RPM1 1640, 5% BSA, 
25 mM Hepes, pH 7.5, 0.020/o sodium azide) resuspended in binding 
buffer, and counted using trypan blue as an indicator of viability. Each 
reaction contained approximately 5 x 1 O5 cells, [‘*sl]-EPO (0.5 nM), and 
either no competitor, peptide or dimer preparation in a final volume of 
200 pl. The binding reactions (in duplicate) were incubated overnight at 
4%. Following binding, the tubes were centrifuged at 12,000 rpm for 
1 min at 4°C. The supernatant was removed, the cell pellet was resus- 
pended in 100 ul binding buffer, and layered onto 0.7 ml of bovine calf 
serum. The tubes were centrifuged at 12,000 rpm for 5 min at 4“C, the 
supernatant was removed, the bottom of the tubes snipped off, and the 
cell pellets counted in a Micromedic ME plus gamma counter. Nonspe- 
cific binding was determined by incubating cells with [1*51]-labeled EPO 
and a 1 OO-fold excess of nonradioactive EPO. 
EPO-dependent cell proliferation assays 
Cell line FDC-PlIER, an EPO-dependent line that expresses the 
murine EPO receptor, was grown and maintained as described previ- 
ously [16,26]. The hypersensitive cell line FDC-Pl /trER that expresses 
a functional truncated human EPO receptor (missing the carboxy-termi- 
nal 40 amino acids) and a cell line expressing a full length human EPO 
receptor, FDC-PI /HER were also used. All three cell lines exhibit EPO- 
dependent cellular proliferation and their use has been described [16]. 
Briefly, cells were maintained in RPMI 1640 media (GibcolBRL) con- 
taining 10% heat-inactivated fetal calf serum and 10 units/ml of recom- 
binant human EPO. For the proliferation assay, cells were grown to 
stationary phase, centrifuged, washed with RPMI 1640 media (no 
EPO), and grown for an additional 24 h without EPO. The cells were 
then counted, resuspended at 800,000 cells/ml and dispensed at 
40,000 cells per well. Stock solutions of the peptide dimers (5 mM in 
PBS) and peptide (10 mM in DMSO) were prepared and dispensed in 
triplicate to final concentrations of 1 x 1 O-lo M to 1 x 1U5 M and 
adjusted to a final volume of 0.2 ml. Final DMSO concentrations of 
0.10/o (v/v, maximal) or less were shown to have no cellular toxicity or 
stimulatoty effects (data not shown). After a 42 h incubation at 37’%, 
1 uCi per well of [3H]thymidine was added and the incubation contin- 
ued for 6 h, at which time the cells were harvested and counted to 
assess [sH]thymidine incorporation as a measure of cell proliferation. 
Results are expressed as the amount of peptide or dimer peptide nec- 
essary to yield one half of the maximal activity obtained with recombi- 
nant EPO in each assay set. A standard EPO dose-response curve 
was generated within each assay. 
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Dimerization of EBP by EPO mimetic peptides 
EBP [22] was used to study the ability of EPO mimetic peptides to 
mediate dimerization of the ligand binding domain of the EPO receptor. 
Peptide-mediated dimerization was stabilized for study using the non- 
water soluble homobifunctional sulfhydryl reactive cross-linking 
reagent, DPDPB 17,161. Briefly, EBP (22 uM) was incubated in the 
presence or absence of DPDPB (1 .l mM) and variable concentrations 
of EMPl or the EMPl -PEG dimer in 75 pl of PBS, pH 7.5 with all 
reactions and controls containing a final concentration of 4.4% DMSO 
and 0.007% TFA. These samples were incubated for 4 h at room tem- 
perature and stored at 4’C for 12 h before analysis on reducing and 
nonreducing SDS-PAGE. 
Polycythemic exhypoxic mouse bioassay 
Peptides were assayed for activity in viva in a polycythemic mouse 
bioassay [27]. BDFl mice were allowed to acclimatize to ambient con- 
ditions for 7-l 0 days. Body weight was determined for each animal and 
low-weight animals (< 15 g) were excluded. Mice were introduced to 
hypobaric chambers and were kept in a conditioning cycle of 18 h of 
0.40 +I- 0.02 atm, and 6 h at ambient pressure for a total of 14 days. 
Following the 14 day period, mice were removed to ambient pressure 
for 72 h prior to sample administration. Test samples or recombinant 
human EPO standards were diluted in assay vehicle, 0.1% BSA in PBS. 
Peptide sample stock solutions were first solubilized in DMSO. Peptide 
dimers were solubilized in PBS. Control groups included one group of 
vehicle alone, and one group of (DMSO) at a final concentration of 1 o/,. 
Each dose group contained 10 mice. Mice were injected subcuta- 
neously (scruff of neck) with 0.5 ml of the appropriate sample. Then, 48 
hours following the sample injection, the mice were administered an 
intraperitoneal injection of 0.2 ml of [ssFe] (approx. 18.0 pCi/mg, 
DuPont, NEN), 0.40 uCi per mouse. Mouse body weight was deter- 
mined 24 h following [aeFel administration and the mice were sacri- 
ficed 48 h after the [59FeI injection. Blood was collected from each 
animal by cardiac puncture and hematocrits determined (heparin was 
used as the anti-coagulant). Each blood sample (0.2 ml) was analyzed 
for [59Fe] incorporation in a Packard gamma counter. Mice that had 
hematocrit values less than 530/o were eliminated. 
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